Literature DB >> 20875471

Chromatin-mediated regulation of cytomegalovirus gene expression.

Matthew B Reeves1.   

Abstract

Following primary infection, whether Human cytomegalovirus (HCMV) enters either the latent or lytic lifecycle is dependent on the phenotype of the cell type infected. Multiple cell types are permissive for lytic infection with HCMV whereas, in contrast, well characterized sites of latency are restricted to a very specific population of CD34+ cells resident in the bone marrow and the immature myeloid cells they give rise to. It is becoming increasingly clear that one of the mechanisms that promote HCMV latency involves the recruitment of histone proteins to the major immediate early promoter (MIEP) which are subject to post-translational modifications that promote a transcriptionally inactive state. Integral to this, is the role of cellular transcriptional repressors that interact with histone modifying enzymes that promote and maintain this repressed state during latency. Crucially, the chromatin associated with the MIEP is dynamically regulated-myeloid cell differentiation triggers the acetylation of histones bound to the MIEP which is concomitant with the reactivation of IE gene expression and re-entry into lytic infection. Interestingly, this dynamic regulation of the MIEP by chromatin structure in latency extends not only into lytic infection but also for the regulation of multiple viral promoters in all phases of infection. HCMV lytic infection is characterised by a timely and co-ordinated pattern of gene expression that now has been shown to correlate with active post-translational modification of the histones associated with early and late promoters. These effects are mediated by the major IE products (IE72 and IE86) which physically and functionally interact with histone modifying enzymes resulting in the efficient activation of viral gene expression. Thus chromatin appears to play an important role in gene regulation in all phases of infection. Furthermore, these studies are highly suggestive that an intrinsic cellular anti-viral response to incoming viral genomes is to promote chromatinisation into a transcriptionally repressed state which the virus must overcome to establish a lytic infection. What is becoming evident is that chromatin structure is becoming as increasingly important for the regulation of viral gene expression as it is for cellular gene expression and thus understanding the mechanisms employed by HCMV to modulate chromatin function could have broader implications on our understanding of the control of gene expression in general.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875471      PMCID: PMC5419498          DOI: 10.1016/j.virusres.2010.09.019

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  130 in total

1.  Electron microscopic and biochemical evidence that chromatin structure is a repeating unit.

Authors:  P Oudet; M Gross-Bellard; P Chambon
Journal:  Cell       Date:  1975-04       Impact factor: 41.582

2.  GATA1 function, a paradigm for transcription factors in hematopoiesis.

Authors:  Rita Ferreira; Kinuko Ohneda; Masayuki Yamamoto; Sjaak Philipsen
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

3.  A deletion mutant in the human cytomegalovirus gene encoding IE1(491aa) is replication defective due to a failure in autoregulation.

Authors:  E S Mocarski; G W Kemble; J M Lyle; R F Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Human cytomegalovirus latent infection of granulocyte-macrophage progenitors.

Authors:  K Kondo; H Kaneshima; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

5.  Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors.

Authors:  C Söderberg-Nauclér; K N Fish; J A Nelson
Journal:  Cell       Date:  1997-10-03       Impact factor: 41.582

6.  HCMV IE2-mediated inhibition of HAT activity downregulates p53 function.

Authors:  Chih-Hung Hsu; Margaret D T Chang; Kang-Yu Tai; Yu-Ting Yang; Pei-Shan Wang; Chi-Ju Chen; Yan-Hsiung Wang; Sheng-Chung Lee; Cheng-Wen Wu; Li-Jung Juan
Journal:  EMBO J       Date:  2004-05-13       Impact factor: 11.598

7.  A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection.

Authors:  Christina Jenkins; Allison Abendroth; Barry Slobedman
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Daxx-mediated accumulation of human cytomegalovirus tegument protein pp71 at ND10 facilitates initiation of viral infection at these nuclear domains.

Authors:  Alexander M Ishov; Olga V Vladimirova; Gerd G Maul
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 9.  Aspects of human cytomegalovirus latency and reactivation.

Authors:  M Reeves; J Sinclair
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

10.  Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors.

Authors:  M Mendelson; S Monard; P Sissons; J Sinclair
Journal:  J Gen Virol       Date:  1996-12       Impact factor: 3.891

View more
  35 in total

1.  Proteomic profiling of the human cytomegalovirus UL35 gene products reveals a role for UL35 in the DNA repair response.

Authors:  Jayme Salsman; Madhav Jagannathan; Patrick Paladino; Pak-Kei Chan; Graham Dellaire; Brian Raught; Lori Frappier
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Histone H3 lysine 4 methylation marks postreplicative human cytomegalovirus chromatin.

Authors:  Alexandra Nitzsche; Charlotte Steinhäusser; Katrin Mücke; Christina Paulus; Michael Nevels
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

3.  Dynamic interactions between Bombyx mori nucleopolyhedrovirus and its host cells revealed by transcriptome analysis.

Authors:  Jian Xue; Nan Qiao; Wei Zhang; Ruo-Lin Cheng; Xiao-Qin Zhang; Yan-Yuan Bao; Yi-Peng Xu; Lin-Zhu Gu; Jing-Dong Jackie Han; Chuan-Xi Zhang
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Cytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

5.  Transcription of true late (γ2) cytomegalovirus genes requires UL92 function that is conserved among beta- and gammaherpesviruses.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

6.  Infected T98G glioblastoma cells support human cytomegalovirus reactivation from latency.

Authors:  Shuang Cheng; Xuan Jiang; Bo Yang; Le Wen; Fei Zhao; Wen-Bo Zeng; Xi-Juan Liu; Xiao Dong; Jin-Yan Sun; Ying-Zi Ming; Hua Zhu; Simon Rayner; Qiyi Tang; Elizabeth Fortunato; Min-Hua Luo
Journal:  Virology       Date:  2017-07-24       Impact factor: 3.616

7.  Canonical and Variant Forms of Histone H3 Are Deposited onto the Human Cytomegalovirus Genome during Lytic and Latent Infections.

Authors:  Emily R Albright; Robert F Kalejta
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

8.  Insertion of myeloid-active elements into the human cytomegalovirus major immediate early promoter is not sufficient to drive its activation upon infection of undifferentiated myeloid cells.

Authors:  Qingsong Qin; Song Hee Lee; Ruibin Liang; Robert F Kalejta
Journal:  Virology       Date:  2013-10-24       Impact factor: 3.616

9.  The rise of epigenetic targets for the development of novel antivirals.

Authors:  Thomas M Kristie
Journal:  Expert Rev Anti Infect Ther       Date:  2012-12       Impact factor: 5.091

Review 10.  Snapshots: chromatin control of viral infection.

Authors:  David M Knipe; Paul M Lieberman; Jae U Jung; Alison A McBride; Kevin V Morris; Melanie Ott; David Margolis; Amelia Nieto; Michael Nevels; Robin J Parks; Thomas M Kristie
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.